Please assess the completion status of the following clinical trial:

Trial Title: A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria Part A~* Participant has one of the selected solid tumors with no distant metastases, and is more than 8 weeks from completion of definitive therapy with intention to cure. Selected Solid Tumors: Stage I to III non-small cell lung carcinoma (NSCLC); Stage III breast cancer; Stage IIB or III melanoma; Stage II or III upper gastrointestinal tract carcinoma (e.g., esophagus, stomach, gallbladder, pancreas); Stage III colon carcinoma; Stage II, III, or IV (M0 only) renal cell carcinoma; Stage II, III, or IV (M0 only) bladder carcinoma; clinically-localized prostate carcinoma~* Participant has adequate organ function.~* Female participant of childbearing potential has a negative serum pregnancy test within 3 days of study enrollment.~Exclusion Criteria Part A~* Participant has known hypersensitivity to any component of study vaccine.~* Participant has a history of clinically significant cardiac conditions, including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or New York Heart Association (NYHA) Class III or IV congestive heart failure. Participant must have no clinically significant electrocardiogram (ECG) abnormalities and not have a pacemaker or cardioverter/defibrillator implanted.~* Participant has undergone splenectomy or has any history of autoimmune disorder.~* Participant has received immunosuppressive treatment within 1 month prior to enrollment.~* Participant has known acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections.~* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of study entry.~* Participant is pregnant or breastfeeding, or expecting to conceive at any time during the study or within 1 year after receiving the last vaccination.~* Participant is known to be Human Immunodeficiency Virus (HIV)-seropositive.~* Participant has known history of Hepatitis B or C or active Hepatitis A.~* Participant has been vaccinated for any disease or for prophylaxis within 1 month prior to the first vaccination.~* The participant has been diagnosed with Systemic Lupus Erythematosus (SLE)~Inclusion Criteria Part B~* Participant must have completed their respective vaccination Treatment Group regimen for Part A of this study.~* Participant must have completed a ≥12 week safety observation period prior to receiving their first V934-EP boost.~Exclusion Criteria Part B~* Participant has new or metastatic tumor lesions since enrollment in Part A.~* Participant has developed any significant cardiac conditions since enrollment in Part A including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or NYHA Class III or IV congestive heart failure.~* Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.~* Participant has received immunosuppressive treatment within 1 month prior to enrollment in Part B~* Participant has developed any acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections~* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of entry to Part B.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: V935 LD (Type: EXPERIMENTAL): Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
- Part A: V934 LD(3)+V935 LD (Type: EXPERIMENTAL): Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
- Part A: V935 HD (Type: EXPERIMENTAL): Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
- Part A: V934 HD(3)+V935 HD (Type: EXPERIMENTAL): Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
- Part A: V934 HD(5)+V935 HD (Type: EXPERIMENTAL): Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
- Part B: V935 LD/V934 Booster (Type: EXPERIMENTAL): Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
- Part B: V934 LD(3)+V935 LD/V934 Booster (Type: EXPERIMENTAL): Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
- Part B: V935 HD/V934 Booster (Type: EXPERIMENTAL): Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
- Part B: V934 HD(3)+V935 HD/V934 Booster (Type: EXPERIMENTAL): Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
- Part B: V934 HD(5)+V935 HD/V934 Booster (Type: EXPERIMENTAL): Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).